GC Selected for 'COVID-19 mRNA Vaccine Phase 1 Clinical Trial Support Project'

Korea Disease Control Agency Recognizes mRNA-LNP Platform Technology
Aiming for IND Approval of Phase 1 Clinical Trials Within This Year

GCGC announced on December 15 that it has been selected as a clinical phase 1 research support company for the 'Pandemic Preparedness mRNA Vaccine Development Support Project' organized by the Korea Disease Control and Prevention Agency.

This project selects only two out of four companies chosen at the non-clinical stage to support clinical phase 1 trials.

GC is the only company in Korea capable of independently handling the entire process from candidate selection to manufacturing and production based on its proprietary mRNA-LNP platform. In particular, the company has been recognized for its platform competitiveness by possessing key technologies such as ▲UTR patents ▲artificial intelligence (AI)-based codon optimization ▲LNP technology that enhances delivery efficiency.

The company aims to obtain IND approval for a COVID-19 mRNA vaccine candidate within this year. After approval, it plans to proceed swiftly with research and submit the IND application for phase 2 clinical trials in the second half of next year.

Jung Jaeuk, Head of R&D at GC, stated, "Securing a domestic mRNA vaccine platform is a crucial task to strengthen the nation's epidemic response capabilities," adding, "We will use this opportunity to further accelerate our development speed."

This content was produced with the assistance of AI translation services.